Michael Klufas, MD
Geriatric Medicine · Cumberland, RINPI 1205822277
Payments from drug & device makers
Across 1,749 payments — averaging $21.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$4K
- Johnson & Johnson$3K
- Teva Pharmaceuticals USA, Inc.$3K
- Pfizer$3K
- Amgen$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- plus $19K from 54 others
What the payments were for
- Speaking & faculty fees$570%
- Food & beverage$36,51698%
- Education$5782%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$37,151 in reported general payments places this provider in the 95th percentile of 28 geriatric medicine providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,089 | $379,673 |
| TrulicityDulaglutide | 267 | $256,110 |
| IngrezzaValbenazine Tosylate | 52 | $221,980 |
| JardianceEmpagliflozin | 315 | $169,529 |
| OzempicSemaglutide | 163 | $166,729 |
| Invega SustennaPaliperidone Palmitate | 57 | $160,547 |
| Invega TrinzaPaliperidone Palmitate | 11 | $106,292 |
| XareltoRivaroxaban | 280 | $99,444 |
| XifaxanRifaximin | 21 | $68,830 |
| NuplazidPimavanserin Tartrate | 26 | $64,105 |
| MyrbetriqMirabegron | 171 | $61,991 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 84 | $49,554 |
| MounjaroTirzepatide | 39 | $43,211 |
| AptiomEslicarbazepine Acetate | 53 | $33,902 |
| Atorvastatin Calcium | 2,134 | $33,366 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $3,055 | $379,6731,089 claims |
| Johnson & JohnsonInvega Sustenna, Invega Trinza, Xarelto | $3,130 | $366,284348 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $713 | $299,321306 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $846 | $221,98052 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $1,653 | $214,558419 claims |
| Novo NordiskOzempic, Rybelsus | $473 | $195,514188 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta | $627 | $124,801332 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Lokelma | $4,176 | $70,479131 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $585 | $68,83021 claims |
| Acadia Pharmaceuticals IncNuplazid | $253 | $64,10526 claims |
| Astellas Pharma US IncMyrbetriq | $546 | $61,991171 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $626 | $33,90253 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 28 geriatric medicine providers in Rhode Island.
Other geriatric medicine in Cumberland
- Avanish MehtaCumberland$943
- John StoukidesEast Providence$6.5M
- Olimpia RaduRiverside$2K
- Richard BesdineRiverside$740
- Joanna Abi CheblProvidence$552
- Thomas BayerProvidence$519
- Denis MoonanNorth Providence$217
- Edward WestrickWarwick$197
- Julio Defillo DraibyRiverside$151
- Carolina Fonseca ValenciaProvidence$119
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.